Skip to main content
Smart Investors Daily
CR

NASDAQ · CRMD

CorMedix Inc.

Healthcare · Biotechnology

$5.27

Up+$0.19 (+3.74%)

Updated Nov 21, 2026, 9:23 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
924.2M
P/E ratio
5.48
Dividend yield
0.00%
52-week range
$4.47 – $9.09
Volume
3.61M
Avg. volume
2.73M

Price performance · CRMD

CRMD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

CRMD closed at $5.27 after 21 trading sessions, down 32.87% for the selected period.

Last close
$5.27
Period change
-32.87%
Period low
$4.50
Period high
$8.20
Daily close
View OHLC price history
CRMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$4.96$5.315$4.95$5.273.61M
Nov 19, 2026$4.57$5.155$4.465$5.083.55M
Nov 18, 2026$4.65$4.71$4.485$4.501.6M
Nov 17, 2026$4.79$4.87$4.635$4.671.99M
Nov 16, 2026$5.05$5.2331$4.75$4.823.2M
Nov 13, 2026$4.88$5.055$4.65$4.662.39M
Nov 12, 2026$5.15$5.49$4.815$4.843.68M
Nov 11, 2026$5.33$5.42$5.24$5.301.63M
Nov 10, 2026$5.49$5.675$5.29$5.372.34M
Nov 9, 2026$5.47$5.56$5.16$5.472.33M
Nov 6, 2026$5.25$5.335$5.10$5.321.62M
Nov 5, 2026$5.75$5.77$5.2114$5.231.83M
Nov 4, 2026$5.71$5.79$5.58$5.661.49M
Nov 3, 2026$5.35$5.60$5.30$5.562.46M
Nov 2, 2026$5.70$5.75$5.34$5.393.3M
Oct 30, 2026$7.68$7.68$5.63$5.6957.02M
Oct 29, 2026$8.34$8.3545$7.455$7.641.89M
Oct 28, 2026$7.95$8.22$7.90$8.201.16M
Oct 27, 2026$7.91$8.11$7.80$8.001M
Oct 26, 2026$8.06$8.09$7.7622$7.941.13M
Oct 23, 2026$8.01$8.11$7.79$7.85894.54K

Latest CRMD news

The latest Smart Investors Daily articles mentioning CRMD.

CRMD research

Overview

Company profile and research snapshot.

Company profile

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$19.50
Implied upside
—
Analysts
—
CRMD recent ratings
DateFirmRatingTarget
Nov 13, 2026RBC CapitalOutperform—
Nov 13, 2026OppenheimerOutperform—
Nov 12, 2026NeedhamBuy—
Nov 10, 2026RBC CapitalOutperform—
Nov 10, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.